These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9210915)

  • 1. Pulmonary hypertension in two patients with type I Gaucher disease while on alglucerase therapy.
    Harats D; Pauzner R; Elstein D; Many A; Klutstein MW; Kramer MR; Farfel Z; Zimran A
    Acta Haematol; 1997; 98(1):47-50. PubMed ID: 9210915
    [No Abstract]   [Full Text] [Related]  

  • 2. Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome.
    Dawson A; Elias DJ; Rubenson D; Bartz SH; Garver PR; Kay AC; Bloor CM; Beutler E
    Ann Intern Med; 1996 Dec; 125(11):901-4. PubMed ID: 8967670
    [No Abstract]   [Full Text] [Related]  

  • 3. Alglucerase treatment of type 1 Gaucher disease with pulmonary involvement.
    Martinez Odrizola P; Ferrero O; Jauregui I; Miguel F
    Respir Med; 1998 Dec; 92(12):1370-2. PubMed ID: 10197233
    [No Abstract]   [Full Text] [Related]  

  • 4. Pulmonary hypertension in type 1 Gaucher's disease. Comité d'Evaluation du Traitement de la Maladie de Gaucher.
    Belmatoug N; Launay O; Carbon C
    Lancet; 1998 Jul; 352(9123):240. PubMed ID: 9683246
    [No Abstract]   [Full Text] [Related]  

  • 5. Alglucerase (Ceredase).
    Wiltink EH; Hollak CE
    Pharm World Sci; 1996 Jan; 18(1):16-9. PubMed ID: 8861826
    [No Abstract]   [Full Text] [Related]  

  • 6. Alglucerase for Gaucher's disease.
    Med Lett Drugs Ther; 1991 Aug; 33(851):82. PubMed ID: 1865852
    [No Abstract]   [Full Text] [Related]  

  • 7. Pulmonary arterial hypertension with plexogenic arteriopathy in enzyme-substituted Gaucher disease.
    den Bakker MA; Grünberg K; Boonstra A; van Hal PT; Hollak CE
    Histopathology; 2012 Aug; 61(2):324-6. PubMed ID: 22690977
    [No Abstract]   [Full Text] [Related]  

  • 8. Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient.
    Aviner S; Levy Y; Yaniv I; Cohen IJ
    Blood Cells Mol Dis; 1999 Apr; 25(2):92-4. PubMed ID: 10389590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gaucher disease: resetting the clinical and scientific agenda.
    Mistry PK; Weinreb NJ; Brady RO; Grabowski GA
    Am J Hematol; 2009 Apr; 84(4):205-7. PubMed ID: 19296473
    [No Abstract]   [Full Text] [Related]  

  • 10. IV epoprostenol in Gaucher's disease.
    Elstein D; Zimran A
    Chest; 2000 Jun; 117(6):1821. PubMed ID: 10858430
    [No Abstract]   [Full Text] [Related]  

  • 11. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
    Zimran A; Morris E; Mengel E; Kaplan P; Belmatoug N; Hughes DA; Malinova V; Heitner R; Sobreira E; Mrsić M; Granovsky-Grisaru S; Amato D; vom Dahl S
    Blood Cells Mol Dis; 2009; 43(3):264-88. PubMed ID: 19502088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary hypertension in Gaucher's disease.
    Pastores GM; Miller A
    Lancet; 1998 Aug; 352(9127):580. PubMed ID: 9716094
    [No Abstract]   [Full Text] [Related]  

  • 13. Alglucerase enzyme replacement therapy used safely and effectively throughout the whole pregnancy of a Gaucher disease patient.
    Aporta Rodriguez R; Escobar Vedia JL; Navarro Castro AM; Aguilar García G; Cabrera Torres A
    Haematologica; 1998 Sep; 83(9):852-3. PubMed ID: 9825582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Enzyme substitution in Gauscher disease].
    Steensberg J; Nielsen KG; Brandt NJ
    Ugeskr Laeger; 1998 Jun; 160(26):3900-3. PubMed ID: 9656829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gaucher disease type 1--therapeutic results of enzyme substitution].
    Steensberg J; Nielsen KG; Brandt NJ
    Ugeskr Laeger; 1998 Jun; 160(26):3929-30. PubMed ID: 9656836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation analysis of the acid beta-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to alglucerase.
    Germain DP; Kaneski CR; Brady RO
    Mutat Res; 2001 Nov; 483(1-2):89-94. PubMed ID: 11600137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic fractures may develop in Gaucher patients receiving enzyme replacement therapy.
    Sidransky E; Ginns EI; Westman JA; Ehmann WC
    Am J Hematol; 1994 Nov; 47(3):247-9. PubMed ID: 7942798
    [No Abstract]   [Full Text] [Related]  

  • 18. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
    Elstein D; Cohn GM; Wang N; Djordjevic M; Brutaru C; Zimran A
    Blood Cells Mol Dis; 2011 Jan; 46(1):119-23. PubMed ID: 20727796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholangiocarcinoma occurring in a patient with type 1 Gaucher disease treated with velaglucerase alfa enzyme replacement therapy: First case report.
    Holubar J; Bres V; Costes-Martineau V; Pers YM
    Blood Cells Mol Dis; 2018 Feb; 68():112-114. PubMed ID: 28559130
    [No Abstract]   [Full Text] [Related]  

  • 20. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy.
    Langeveld M; de Fost M; Aerts JM; Sauerwein HP; Hollak CE
    Blood Cells Mol Dis; 2008; 40(3):428-32. PubMed ID: 17950007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.